News

Tangen Biosciences Awarded Expanded Second Phase
of Contract

BRANFORD, Conn.–(BUSINESS WIRE)–The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) awarded Tangen Biosciences, Inc. the second phase of a contract to develop a field-deployable Anthrax diagnostic assay and expand the research to an antimicrobial resistance diagnostic assay.

The BARDA contract with Tangen Biosciences is, potentially, a 3.5-year project, which is expected to advance and expand the ability to combat the threat of Bacillus anthracis by utilizing the TangenDxTM Molecular Diagnostic System. TangenDx will provide a rapid, highly sensitive, low cost, and fully portable molecular diagnostic platform. The high sensitivity, portability, and speed provided by the Tangen platform is expected to facilitate a more accurate diagnosis of Anthrax, allowing for more effective treatment and improved response to outbreaks. The contract with BARDA will fund the development of the TangenDx instrument platform, with the anticipation of an FDA 510(k) clearance of the Anthrax molecular diagnostic assay and the development of additional tests to detect antimicrobial resistance markers directly from blood.

The first phase of the contract commenced in October 2017 and was valued at $3.2 million. Tangen completed the first phase in February 2019 and delivered a functional TangenDx Instrument with a sensitive Anthrax test. Independent testing by Battelle demonstrated the TangenDx test can detect Anthrax virulence genetic markers with sensitivity as low as, approximately, 5 CFU/ml from 3 ml whole blood samples.

The newly funded second phase of the contract, which started in July 2019, is for $3.8 million. It includes the development of a blood test for a panel of multiple drug resistance markers directly from blood for up to potentially 32 resistance markers or organisms. Dr. John Davidson, Chief Scientific Officer of Tangen stated “The ability to rapidly identify antimicrobial resistance without first culturing blood is a needed tool in the fight against rising antibiotic resistant infectious microbes.”

The project has been funded in part with Federal funds from the Department of Health and Human Services: Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201700028C.

About Tangen Biosciences:

Tangen Biosciences, Inc. was founded in 2013 and is located in Branford, Connecticut. The company developed the TangenDx platform for fast and accurate detection of targeted DNAs and RNAs directly from specimens by using rapid isothermal nucleic acid detection. Use of Tangen’s system, which does not require laboratory facilities, delivers faster, simpler, more sensitive detection at a lower cost than other commercial technologies. The TangenDx platform is on track for infectious disease clinical studies. To learn more, please visit: https://tangenbioscience.com/

Forward-Looking Statements:

This press release contains “forward-looking statements” concerning the development and future commercialization of the company’s products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Tangen Biosciences undertakes no obligation to update any forward-looking statements.

Contacts

Tangen Biosciences, Inc. 
Investor Relations: 
Rebecca Araneo 
Rebecca.Araneo@tangenbioscience.com 
Ph: (203) 433-4045

 

 

June 20, 2019 UTC. Tangen Biosciences Announces $9 Million Series A Financing to Accelerate Development of Disruptive Molecular Diagnostic Platform

BRANFORD, Conn.–(BUSINESS WIRE)– Tangen Biosciences, Inc., a molecular diagnostic company located in Branford, Connecticut, announced that it has closed a $9 million Series A equity round led by Connecticut Innovations (CI), with participation of current and new stockholders, including VC23, Axiom, and Leading Edge Ventures. The financing proceeds will be used to accelerate the company’s innovative platform TangenDx™ to the clinic for two infectious disease tests.

TangenDx™ is a novel isothermal nucleic acid detection platform that enables molecular diagnostic technology to move out of traditional laboratories by providing low cost, portable, and rapid diagnostic capabilities with unparalleled sensitivity for a variety of applications.

“We are impressed by the development of TangenDx™”, said Daniel Wagner, Senior Managing Director of Venture Capital Investments at CI. “The future of diagnostics lies in decentralized testing, and TangenDx™ will bring high quality molecular testing out of the traditional laboratory setting into doctors’ offices, pharmacies, and health-care providers in areas with limited infrastructure.”

Tangen Biosciences is led by CEO, Richard C. Birkmeyer, PhD, an experienced executive who joined the company in November 2018. Rick previously led two start-up diagnostic companies from infancy to successful exits. Tangen also expanded its management team to include Keith Kardos, PhD, acting VP of Clinical Affairs, and Anne Cavanaugh, Director of Finance. Keith has over 25 years of experience managing R&D programs. Keith was formerly employed as the VP of R&D for OraSure Technologies, Inc. and VP of Clinical Affairs for CD Diagnostics. Anne is a successful entrepreneur who co-founded Strategic Diagnostics Inc. (SDI). Strategic Diagnostics became a public company and grew to a $200 million market capitalization with over 200 employees.

In anticipation of a 2020 product launch, Tangen Biosciences will be relocating its office to a new 16,200 square foot facility located in Branford, CT in August 2019.

“I am very excited to be part of Tangen Biosciences. The technology developed by John Nobile and Dr. John Davidson is second to none. A recent evaluation by a third party demonstrated that our technology out-performs any of our competitors by 10X for clinical sensitivity. We will launch two 510(k) clinical studies this year, utilizing product produced in our cGMP-compliant, ISO 8 facility,” said Rick Birkmeyer, President and CEO of Tangen Biosciences.

About Tangen Biosciences:

Tangen Biosciences, Inc. was founded in 2013 and is located in Branford, Connecticut. The company developed the TangenDx™ platform for fast and accurate detection of targeted DNAs and RNAs directly from specimens by using rapid isothermal nucleic acid detection. Use of Tangen’s system, which does not require laboratory facilities and delivers faster, simpler, more sensitive detection; at lower cost than existing commercial technologies. The TangenDx™ platform is on track for infectious disease clinical trials. To learn more, please visit: https://tangenbioscience.com/

About Connecticut Innovations:

Connecticut Innovations (CI) is the leading source of financing and ongoing support for Connecticut’s innovative, growing companies. To maximize growth potential, CI provides venture capital and strategic support for early-stage technology companies; financial support for innovation and collaboration; and connections to its well-established network of partners and professionals. For more information, please visit https://ctinnovations.com/

Forward-Looking Statements:

This press release contains “forward-looking statements” concerning the development and future commercialization of the company’s products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Tangen Biosciences undertakes no obligation to update any forward-looking statements.

Contacts

Tangen Biosciences, Inc. 

Investor Relations: 
Rebecca Araneo 
Rebecca.Araneo@tangenbioscience.com 
Ph: (203) 433-4045

 

 

October 15, 2018.  (Branford, CT) Richard Birkmeyer, PhD, selected as President and CEO of Tangen Biosciences, Inc.

Richard “Rick” Birkmeyer, PhD, has been chosen as the President and CEO of Tangen Biosciences, Inc.  Before joining Tangen Biosciences, Rick was CEO at CD Diagnostics, Inc. The company developed synovial fluid biomarkers using immunoassay technology which have won numerous awards and are now the gold standard in the orthopedic industry.  The company was acquired by Zimmer Biomet in 2017.

“Richard Birkmeyer is a seasoned executive and an accomplished entrepreneur with a proven track record. We are excited and happy to have him on board to lead the company through this important period for Tangen Biosciences,” said Board Chairman Chris McCleod.

Prior to CD, Rick founded Strategic Diagnostics, Inc. a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and life science applications.  As its CEO, Rick grew revenues to $26 million and operated the business profitably.  Rick established and implemented highly successful strategic corporate partnerships with Fortune 100 companies, raised venture capital financing, and completed six acquisitions including utilizing a financial reverse merger in 1996 to create a publicly traded company NASDAQ: (SDIX) and liquidity for SDI’s venture capital investors.

Prior to founding Strategic Diagnostics, Rick was employed by E.I. duPont de Nemours and Company, most recently as a Manufacturing Product Manager responsible for production of 26 immunoassays for the clinical diagnostics market. Rick also serves as a general partner for Leading Edge Ventures.

Rick received his B.S. in Biology from the State University of New York, Plattsburgh and his Ph.D. in biochemistry and immunology from the State University of New York, Binghamton. Rick also completed post-doctoral research in immunogenetics at Iowa State University.

 

September 27, 2017. BARDA awards Contract to Tangen Biosciences, Inc. to Support Development of a Rapid, Deployable, Sensitive Diagnostic Platform to Diagnose Anthrax

BARDA awarded a $3,199,221 base period of a contract to Tangen Biosciences, Inc. of Branford, CT to further advance and expand the ability to combat the threat of Bacillus anthracis with the TangenDx Molecular Diagnostic System (TangenDx™ System), which is a rapid, sensitive, low cost, and field deployable diagnostic assay.

If approved, the TangenDx™ System could be used to determine whether a symptomatic patient had been infected with anthrax-causing Bacillus anthracis bacteria in as little as 15 minutes. Preliminary data indicate that the TangenDx™ System could be as sensitive as current blood cultures with results hours quicker. The test can be based on a wide range of specimen types, including blood, sputum, and other methods of specimen sampling. Tangen will have an Option 1 and possible Option 2 for subsequent funding to complete the development work and to conduct clinical studies for eventual FDA clearance. This could value the contract for up to $9.4 million to develop an Anthrax diagnostic test.

In the wake of an anthrax attack, medical responders need to quickly determine who has been infected so that they can be effectively treated. A rapid, accurate diagnostic test is an essential tool for doctors and other health professionals to effectively triage people who may be infected with anthrax. Such a tool has been long requested by medical responders as a critical component of anthrax preparedness.

Detecting anthrax infections allows for effective treatment. BARDA’s portfolio includes supporting three anthrax antitoxin drugs approved by the FDA.

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201700028C.

 

July 2017 

Tangen Biosciences receives a Notice of Intent to fund the SBIR/NIH phase I grant application for Rapid Detection of Multiple Sepsis Pathogens.

 

April 17, 2017 

Tangen Biosciences  holds Pre-Submission meeting with FDA to discuss parameters for the clinical testing of the TangenDx direct-from-blood Fungal Panel in support of a planned 510(k) submission.

The FDA has reviewed and commented on the study protocol design for the Tangen Candida BSI Panel Kit developed by Tangen Biosciences, Inc.  The recommendations made by the FDA will be incorporated into the study design.  With the recommendations suggested by the FDA, the protocol will be approved by the FDA.

 

February 1, 2017 

Tangen Biosciences has commenced the process of securing FDA clearance for its novel molecular diagnostic platform by submitting a Pre-Submission Package to the Center for Devices and Radiological Health of the Food and Drug Administration.

 

November 2016

Tangen successfully demonstrates the TangenDx Fungal Sepsis Panel at three clinical microbiology labs in the northeast region.

Tangen Biosciences, Inc., successfully demonstrated the TangenDx Candida BSI Panel Kit at the Yale New Haven Hospital, Rhode Island Hospital, Providence, RI, and Danbury Hospital, part of the Western Connecticut Health Network.

 

June 2016

Tangen Biosciences, Inc., has been awarded a Phase I SBIR grant from the National Institutes of Health to develop a rapid molecular assay for the detection of Multiple Drug Resistant Mycobacteria Tuberculosis (MDR-TB) in sputum. 

The grant will fund the development of specific primers to identify 15 different SNPs in the TB genome that confer resistance to front line TB antibiotics. The drug sensitivity test will be added into the existing Tangen TB assay to create a panel that will include accurate diagnosis of TB along with comprehensive drug sensitivity information.  The MDR-TB assay panel will run on a single disposable disk in the TangenDx Instrument, a battery powered, portable, low cost, highly sensitive and simple to use molecular diagnostic platform.

 

Dec 2015

Tangen completes $2MM Seed Round equity financing


http://www.hartfordbusiness.com/article/20151229/NEWS01/151229911/tangen-biosciences-raises-2m-in-equity-funding

A U.S. Securities Exchange Commission filing shows Branford-based Tangen Biosciences, Inc. has raised $2 million in equity and hopes to sell another $1 million.

To date, eight investors have purchased equity in the biotechnology company that is working on a better means of diagnosing tuberculosis around the world.

Connecticut Innovations approved a $150,000 investment in Tangen from its pre-seed fund in January 2014. (Tangen also received funding from a private angel investor.) Later that year, in December, the Connecticut Bioscience Innovation Fund made a $500,000 investment in the Tangen.

As of October 2015, the company has six full-time employees, according to Connecticut Innovations. The filing says proceeds of the offering may be used to pay the salaries of its executive officers in the ordinary course of business.